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GRAFT REJECTION FOLLOWING DOG LEUKOCYTE ANTIGEN
(DLA)-IDENTICAL NONMYELOABLATIVE HEMATOPOIETIC CELL TRANS-
PLANTATION (HCT) RESULTS IN LONG-TERM INCREASES IN HOST
T REGULATORY (TREG) CELLS
Georges, G.E.1,2, Lesnikova, M.1, Hwang, B.1, Abrams, K.1,
Nash, R.A.1,2. 1Fred Hutchinson Cancer Research Center, Seattle, WA;
2University of Washington, Seattle, WA.
In the canine HCT model, graft rejection occurred immediately
with no evidence of transient donor chimerism among all recipients
who were sensitized with whole blood transfusions given prior to
conditioning from their respective DLA-identical HCT donor. In
a separate study, in order to identify alternative nonmyeloablative
conditioning regimens such as 1 Gy total body irradiation (TBI)
with post-grafting pharmacological immunosuppression, we ob-
served a cohort of recipient dogs (not previously sensitized with
transfusions), who had transient donor/host mixed chimerism fol-
lowed by graft rejection. To evaluate if these recipients were now
sensitized to donor antigens, 27 dogs who had transient mixed chi-
merism followed by graft rejection after 1st HCT were re-condi-
tioned with 2 Gy TBI and given a second HCT from the original
donor. Recipient dogs developed either transient or stable mixed
chimerism in 37% and 19%, respectively. We hypothesized that
themechanism for donor-specific tolerance seen following rejection
of a hematopoietic cell graft was due to a sustained increase of host
Treg cells. We evaluated the induction of Treg in the peripheral
blood of 10 dogs conditioned with 0.5, 1 or 2 Gy TBI that had tran-
sient donor chimerism followed by rejection of a DLA-identical
HCT compared to 10 normal (not transplanted) dogs. We devel-
oped a quantitative PCR assay, using canine specific foxP3 primers
to amplify cDNA from sorted T cells. Recipient T cells were cul-
tured with the respective DLA-identical donor dendritic cells to in-
duce allostimulation andwere assessed forCD41CD251FoxP31 by
flow cytometry. Also, intracellular T cell interferon-g and TNF-
a was measured by flow cytometry. We determined that indepen-
dent of the time after HCT rejection (range, 4–96 weeks) or dura-
tion/degree of transient mixed chimerism, Treg cells were
significantly increased in dogs that had graft rejection compared
to untreated dogs. There was a 4-fold increase in foxP3 tran-
scripts/cell, consistent with the induction of CD41CD251FoxP31
Treg cells in dogs with prior transient mixed chimerism and graft re-
jection. However CD41TNFa1 and Inf-g1 cells were also in-
creased, reflecting activation of allo-immune effector cells
induced by HCT rejection. The results are consistent with the hy-
pothesis that acceptance of second HCT grafts may occur after 1st
transient mixed chimerism because of immune mechanisms favor-
ing Treg induction over pro-inflammatory cytokine producing im-
mune cells.T Cell Regulatory and Effector Phenotype in Dogs
Previously Rejected102HCT* Untreated p-valueT Cell Assay Mean ± Standard Deviation t-testfoxP3 transcripts/105 T cells 14,208 ± 6886 3,475 ± 1973 #0.0001% CD41CD251 6.9 ± 5.4 1.1 ± 0.3 #0.047% CD41CD251FoxP31 7.2 ± 6.1 0.8 ± 0.4 #0.048% CD41TNFa1 18.1 ± 5.1 7.7 ± 4.7 #0.001% CD41Infg1 17.7 ± 5.1 12.6 ± 4.0 #0.031% CD81Infg1 25.3 ± 7.8 17.1 ± 4.6 #0.014*Dogs with graft rejection after transient mixed chimerism follow-
ing 1st nonmyeloablative HCT.276
MYELOABLATIVE TRANSPLANTATION FROMMATCHED SIBLINGS (MSD)
USING A DAILY INTRAVENOUS BUSULFAN (BU)/FLUDARABINE (FLU)
REGIMEN WITH THYMOGLOBULIN (TG): ANALYSIS INVOLVING 200
PATIENTS INDICATES LOW TRANSPLANT-RELATED MORTALITY (TRM)
IN ALL BUT OLDER PATIENTS WITH HIGH-RISK DISEASE
Russell, J.1, Duan, Q.1, Chaudhry, A.1, Brown, C.1, Bahlis, N.1,
Savoie, L.1, Daly, A.1, Geddes, M.1, Storek, J.1, Balogh, A.1,
Zacarias, N.1, Duggan, P.1, Quinlan, D.1, Turner, R.2, Larratt, L.2,
Stewart, D.1. 1Tom Baker Cancer/Foothills Hospital, Calgary, AB,
Canada; 2Cross Cancer Institute, Edmonton, AB, Canada.
We aimed to identify MSD transplant recipients given Flu/Bu
andGVHDprophylaxis incorporatingTGwhomay be at particular
risk of TRM and perhaps merit some modification of the protocol.
Between 1999 and 2005 200 patients (pts) aged 18–65 (median 46)
received Flu 50 mg/m2 daily 5 and IV Bu 3.2 mg/kg daily 4. 46
had additional total body irradiation 200 cGy 2. GVHD prophy-
laxis was CSA, methotrexate and TG (Genzyme) 4.5 mg/kg total
dose. Cell source was mobilized blood cells in 172 and marrow in
28. At follow-up of survivors of 13–87 months (median 42) low-
risk (LR, acute leukemia CR1/CR2, CML CP1) pts had projected
5 year TRM and overall survival (OS) of 4% and 76% for pts
#45 years old (n 5 54) vs 6% and 83% for those .45 (n 5 31).
For high-risk (HR) pts TRM was 6% vs 27% (18% at one year)
(p 5 0.04) and OS 64% vs 37% (p 5 0.47) in younger (n 5 40)
and older (n 5 75) pts respectively. To correct for imbalance in
HR diagnoses we matched each of 17 younger HR pts with 2 older
HR (OHR) pts by diagnosis and details of stage and thereafter for
other risk factors. OS was 70% vs 37% (p 5 0.02), TRM 0 vs
34% (p5 0.02) and relapse 63% (48% at 3 years) vs 46% at 5 years
(p 5 ns) respectively. For a more robust analysis OHR pts were
compared with the other 3 groups combined giving TRM of 27%
vs 5% respectively (p 5 0.002). Incidence of aGVHD grade II-
IV, aGVHD grade III-IV and cGVHD was 23% vs 10% (p 5
0.02), 4% vs 2% (p5 ns) and 66% vs 41% (p5 0.001) respectively.
Nine of 14 non-relapse deaths in the OHR group were related to
GVHD or its treatment compared with 3 of 6 in all others (p value
for GHVD related death 5 0.01). Multivariate analysis of OS and
DFS correcting for potentially confounding pretransplant factors
idenitified only the HRO patients as having significantly increased
risk (RR 3.32, CI 1.71–6.47, p\ 0.0001 and RR 3.32, CI 1.71–
6.43, p\ 0.0001 respectively). We conclude that the effect of age
on TRM is only apparent in HR pts and is not explained by hetero-
geneity in diagnoses. HRO pts experience more GVHD and more
GVHD related death than others. TRM is no higher than reported
with many non-myeloablative regimens, justification for our prac-
tice of treating all pts with the same regimen. Additional GVHD
prophylaxis might help the HRO pts.277
A PROSPECTIVE EVALUATION OF THE EFFECT OF POLYOMA (BK) VIRUS
INFECTION ON THE INCIDENCE OF HEMORRHAGIC CYSTITIS (HC)
AFTER UNRELATED DONOR ALLOGENEIC HEMATOPOIETIC STEM
CELL TRANSPLANTATION (UD HSCT)
Silva, L.1, Patah, P.1, Szewczyk, N.1, Saliba, R.M.1, Gilman, L.1,
Gulbis, A.1, Neumann, J.1, Walker, J.A.1, Petropoulos, D.1, El-
Zimaity, M.1, Anderlini, P.1, Tarrand, J.2, Ciurea, S.O.1, Shpall, E.1,
Popat, U.1, Jones, R.1, Giralt, S.1, Champlin, R.E.1, de Lima, M.1.
1The University of Texas MD Anderson Cancer Center, Houston, TX;
2The University of Texas MD Anderson Cancer Center, Houston, TX.
Background: BK virus infection is highly prevalent in humans,
and has been associated with development of HC after UD
HSCT. Previously we determined that UDHSCT is independently
associated with higher prevalence of HC (El-Zimaity et al. Blood
2004). In order to further investigate the association of BK with
HC, we hypothesized that the presence of BK virus in the urine as
Poster Session II 103determined by a PCR assay before UD transplant would be associ-
ated with a higher incidence of HC.Methods:We studied prospec-
tively 209 consecutive patients transplanted from 09/05 to 08/07.
Preparative regimens were ablative (n5 118) and reduced intensity
(n5 91); 38 patients (18%) received cyclophosphamide-containing
regimens. GVHD prophylaxis was tacrolimus and mini-methotrex-
ate. Stem cell source was bone marrow (n 5 78), peripheral blood
(n 5 108) and umbilical cord (n 5 23). BK virus quantitative PCR
was performed on urine samples collected at admission for trans-
plant and on days 15, 30, 45 and 60 after transplant. Results: Me-
dian age was 49 years (range, 19–71). Diagnoses were Leukemias
(n 5 161), Multiple Myeloma (n 5 6), Hodgkin’s disease (n 5 7),
Non-Hodgkin’s Lymphomas (n 5 32), and other(n 5 3). Median
follow-up is 246 days (range 7–848). BK PCR was positive in 96 pa-
tients(46%). Number of viral copies ranged from 200 to.200 mil-
lion copies. Twenty-eight patients (13.4%) developed HC, at
a median of 59 days (range 8–225) after HSCT. The 100-day cumu-
lative incidence (using death as a competing risk) of HC in the PCR
positive and negative groups was 13% versus 6% (HR 2.6; 95% CI,
1–6.9; P 5 0.05). The one-year cumulative incidence of HC in the
PCRpositive and negative groups was 16% versus 10% (HR2; 95%
CI, 0.9–4.6; P5 0.09). Incidence of HC (table) was not statistically
significantly increased among recipients of cyclophosphamide-con-
taining regimens or among patients with grade II-IV acute GVHD.
Conclusion: BK viruria pre-HSCT may increase the risk of devel-
oping HC.Incidence of HC
HC Yes (n) %non CTX regimen 20 11
CTX regimen 4 10
GVHD II-IV 8 12
non GVHD 9 10
Ablative regimen 18 15





BK PCR. 200 million copies 2 25
BK PCR\200 million copies 13 15HC: Hemorrhagic Cystitis; CTX: Cyclophosphamide; PBSC:
Peripheral Blood Stem Cell; BM Bone Marrow; CB: Cord
Blood.278
TREOSULFAN PLUS FLUDARABINE FOR ALLOGENEIC HEMATOPOIETIC
CELL TRANSPLANTATION (HCT) IN PATIENTS WITH ACUTE LEUKEMIA
AND MYELODYSPLASTIC SYNDROME
Nemecek, E.R.1, Ly, B.2, Kovacsovics, T.2, Maziarz, R.T.2,
Baumgart, J.3, Sanders, J.E.4, Deeg, H.J.4. 1Oregon Health & Science
University, Portland, OR; 2Oregon Health & Science University,
Portland, OR; 3Medac GmbH, Hamburg, Germany; 4Fred Hutchinson
Cancer Research Center, Seattle, WA.
Myeloablative regimens followed by allogeneic HCT are effec-
tive in eradicating leukemia, but are associated with a moderately
high risk for regimen-related toxicity (RRT) and transplant-related
mortality (TRM). Nonmyeloablative and reduced intensity regi-
mens, variably defined, have been used with resulting decreased
RRT and NRM, but also higher rates of relapse compared to mye-
loablative regimens. Thus, there is a need to explore alternative reg-
imens with sufficient intensity to mediate anti-leukemic activity
without increasing RRT or TRM. The objective of this ongoing
study was to determine the optimum dose of a new agent, treosul-
fan, in combination with fludarabine prior to allogeneicHCT in pa-
tients with acute myeloid (AML) or lymphoblastic leukemia (ALL)
or myelodysplastic syndrome (MDS). ‘‘Optimal’’ dose was deter-
mined by safety and efficacy, as defined by incidence of severe/fatal
RRT, graft failure and TRM. Thirty-six patients (8 children and 28adults$ 18 years), with a median of 41 (5–58) years, and diagnosed
with AML in first (n 5 19), second remission (n 5 7) or not in re-
mission (n 5 4), ALL in second remission (n 5 2) or MDS (n 5
4) have been treated. Patients were considered to be at high risk
for TRM because of aggressive therapy for a prior malignancy, co-
morbid conditions or previousHCT. Patients received treosulfan at
12 (n5 5) or 14 g/m2/day (n5 31) on days -6 to -4, and fludarabine
(30 mg/kg/day) on days -6 to -2. GVHD prophylaxis was with ta-
crolimus andmethotrexate (n5 35) or cyclosporine andmethotrex-
ate (n 5 1). Donors were HLA-matched siblings (n 5 19) or
unrelated volunteers (n 5 17); source of stem cells were bone mar-
row (n5 7) or filgrastim-mobilized peripheral blood cells (n5 29).
Neutrophil engraftment occurred at a median of 18 (11–30) days.
Grade II-IV acute graft-versus-host disease (GVHD) was observed
in 9 of 36 patients, and chronic GVHD in 8 of 23 evaluable patients
surviving beyond post-transplant day 80. Dose-limiting RRT was
observed in 1 of 36 patients (mucositis requiring intubation).
With a median follow-up of 118 (20–575) days, estimated one-
year overall and disease-free survival, relapse and TRM are 83%,
78%, 22% and 0%, respectively. Day-100mortality is 6%.Treosul-
fan/fludarabine is a well-tolerated regimen with promising disease
control and low rates of RRT and TRM in patients with acute leu-
kemia and MDS. Further studies are warranted to evaluate the effi-
cacy of this regimen.279
MODIFICATION OF T CELL RESPONSES BY STEM CELL MOBILIZATION
REQUIRES DIRECT SIGNALLING OF THE T CELL BY G-CSF AND IL-10
MacDonald, K.P.A., Bofinger, H.M., Kuns, R.D., Morris, E.S.,
Don, A.L., Banovic, T., Hill, G.R. Queensland Institute of Medical Re-
search, Brisbane, Queensland, Australia.
G-CSF is increasingly described as a therapy for a diverse range
of diseases and although the mechanisms involved remain unclear,
IL-10 is thought to play a key role as a regulatory effector molecule.
Since G-CSF is used as a stem cell mobilizing agent, we generated
mixed radiation chimeras as stem cell donors in which haemato-
poietic or non-haematopoietic compartments were wild-type
(WT), IL-10-/-, G-CSFR-/- or combinations thereof. T cells from
donors mobilized with G-CSF had impaired ability to induce
GVHD only when the haematopoietic compartment was G-
CSFR competent, whereas G-CSFR signalling within the non-hae-
matopoietic compartment was irrelevant. Furthermore, we demon-
strate that the attenuation of T cell function requires direct
signalling of the T cell by G-CSF. Using G-CSF mobilized IL-
10-/- radiation chimeras as SCT donors, when the non-haemato-
poietic compartment was WT, T cells had impaired ability to
induce GVHD regardless of their ability to secrete IL-10. In con-
trast, T cells from chimeric donors in which the non-haemato-
poietic compartment was IL-10-/- universally induced severe
GVHD. Thus, the induction of regulatory T cell function by
stem cell mobilization occurs as a consequence of direct T cell sig-
nalling byG-CSF in conjunction with IL-10 derived from non-hae-
mopoietic cells. The IL-10 receptor is highly expressed by T cells,
particularly CD41CD251 regulatory T cells and their depletion
from G-CSF treated, but not control grafts, significantly increases
graft-versus-host disease (survival 25% v 75% Treg depleted vs
non-depleted donors P 5 0.002). These studies provide the expla-
nation for the profound effects of G-CSF on T cell function and
demonstrate that IL-10 is required to license regulatory function
but is not required as an effector molecule.280
SEROLOGICAL EVIDENCE OF HEPATITIS C IS ASSOCIATEDWITHWORSE
NON-RELAPSE MORTALITY AND OVERALL SURVIVAL AFTER ALLOGE-
NEIC STEM CELL TRANSPLANTATION
Ramos, C.A., Saliba, R.M., Khorshid, O., de Padua, L., Giralt, S.,
Andersson, B.S., Ueno, N.T., Shpall, E.J., Hosing, C., Qureshi, S.R.,
Champlin, R.E., de Lima, M. The University of Texas MD Anderson
Cancer Center, Houston, TX.
Active chronic hepatitis C (HC) is associated with perturbed im-
munity, but the influence of HC virus infection on the outcomes of
